Head-to-head evidence
Loxapine (Adasuve) vs Paliperidone palmitate (Erzofri)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Loxapine (Adasuve)
Marketed by Lee's Pharmaceutical
NCT00628589 · Phase 3 · completed
The trial randomly assigned 344 participants to inhaled loxapine 5 mg, loxapine 10 mg, or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical agitation measure was significantly improved with both loxapine doses compared with placebo (p=0.0004 and p<0.0001).
Paliperidone palmitate (Erzofri)
Marketed by Luye Pharma Group
NCT03751488 · Phase 1 · completed
In this trial, paliperidone palmitate (INVEGA SUSTENNA) served as the reference comparator against which an investigational competitor formulation, LY03010, was measured for pharmacokinetics; the study was open-label with no blinding, and no results have been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Loxapine (Adasuve)'s landscape · Paliperidone palmitate (Erzofri)'s landscape